Drug Research
Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1
Oragenics, Inc. announced it has entered into an agreement with KBI Biopharma, Inc. for the process transfer, process optimization and cGMP manufacturing of the Company’s intranasal vaccine candidate NT-CoV2-1, which is expressed in a proprietary CHO cell line. The...
Drug Research
WuXi ATU Announces Launch of TESSA Technology to Improve Scalability and Accessibility of Cell and Gene Therapies
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice...
Press Releases
BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo Combination in NSCLC
BioNTech SE announced the expansion of its strategic collaboration with Regeneron to advance the Company’s FixVac candidate BNT116 in combination with Libtayo® (cemiplimab), a PD-1 inhibitor, in advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement...
Press Releases
Global biotechnology leader Amgen breaks ground on new manufacturing facility in North Carolina
Amgen announced the groundbreaking of its newest biomanufacturing facility, located in Holly Springs, North Carolina. The facility, expected to be operational by 2025, will support the growing demand for Amgen's medicines that treat serious illnesses such as cancer and...
Press Releases
Celerion Expands Early Phase Clinical Pharmacology Units
Celerion, a clinical research organization (CRO) to the biopharmaceutical industry, has announced completion of additions to its research capacity and services. This includes the opening of a new Screening and Return Center, upgraded pharmacy compounding suites, expanded Absorption, Distribution,...
Press Releases
Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases
Novartis announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two...
Drug Research
Vibalogics Completes Major Milestone in $50M Cuxhaven Facility Expansion with New 500L Manufacturing Line
Vibalogics, a leading virotherapy contract development and manufacturing organization (CDMO) focused on the production of live– viruses and viral vectors, has announced the completion of its expansion project at its GMP facility in Cuxhaven, Germany.
The new building features biosafety...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















